Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559865 | 1.00 | GBA1 (0.31) | GBA1SIPYGLGBA2GAA | |
| SCHEMBL7296902 | 1.00 | GBA1 (0.31) | GBA1SIPYGLGBA2GAA | |
| SCHEMBL9310298 | 1.00 | GBA1 (0.31) | GBA1SIPYGLGBA2GAA | |
| SCHEMBL1707289 | 1.00 | GBA1 (0.31) | GBA1SIPYGLGBA2GAA | |
| SCHEMBL9685994 | 0.86 | FUCA1 (0.30) | — | |
| SCHEMBL9517983 | 0.82 | — | — | |
| SCHEMBL9517203 | 0.82 | — | — | |
| SCHEMBL9593313 | 0.82 | — | — | |
| SCHEMBL25393489 | 0.80 | — | — | |
| SCHEMBL2030916 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113924303-B | Thienopyrimidine derivatives with steric configuration and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| EP-4121042-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | Purdue Research Foundation (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-113924303-A | Thienopyrimidine derivatives with spatial configuration and application thereof in medicines | 广东东阳光药业有限公司 | 2022-01-11 | — | — | CN | disclosed |
| WO-2021188191-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188191-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-0399633-A1 | Leukotriene B4 derivatives, process for their preparation and their use as medicines | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-11-28 | — | — | EP | disclosed |
| US-4945106-A | Prostaglandins | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-07-31 | — | — | US | disclosed |
| EP-0354529-A2 | Chiral hydroxycarboxylic acids from prochiral diols | GENENCOR INTERNATIONAL, INC. (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0111955-B1 | PROSTAGLANDIN INTERMEDIATES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-09-17 | — | — | EP | disclosed |
| US-4596823-A | Prostaglandins | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-06-24 | — | — | US | disclosed |
| EP-0043292-B1 | PROSTAGLANDINS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-01-15 | — | — | EP | disclosed |
| EP-0111955-A1 | Prostaglandin intermediates | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-06-27 | — | — | EP | disclosed |
| US-4322435-A | FOR THROMBOSIS | SANKYO COMPANY LIMITED (JP) | 1982-03-30 | — | — | US | disclosed |
| WO-1982000142-A1 | PROSTAGLANDINS | JONES R | 1982-01-21 | — | — | WO | disclosed |
| EP-0043292-A2 | Prostaglandins | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136594-A1 | TRICYCLIC P2-LIGAND CONTAINING POTENT HIV-PROTEASE INHIBITORS | CD4, P2RY1, P2RX7 | GBA1 707/4885SI 450/4885PYGL 1165/4885 |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | GBA1 2077/4885SI 2963/4885PYGL 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.